TickerKhojComparison · NSE · data 2026-11-01
AstraZeneca Pharma India Limited vs Jubilant Pharmova Limited
In plain words
Size: AstraZeneca Pharma India Limited is about 1.1 times the market value of Jubilant Pharmova Limited.
Valuation (P/E): AstraZeneca Pharma India Limited 93.8 vs Jubilant Pharmova Limited 41.7.
Return on equity: AstraZeneca Pharma India Limited 23.9% vs Jubilant Pharmova Limited 6%.
Debt to equity: Jubilant Pharmova Limited 0.51 vs AstraZeneca Pharma India Limited 0.13.
Differences in the numbers, not a recommendation of either stock.
Side by side
| ASTRAZEN | JUBLPHARMA | |
|---|---|---|
| Price | ₹6,364.5 | ₹923.8 |
| Market cap | ₹15,918 cr | ₹14,729 cr |
| P/E | 93.8 | 41.7 |
| P/B | — | — |
| ROE | 23.9% | 6.0% |
| ROCE | 25.5% | 6.5% |
| Debt / equity | 0.13 | 0.51 |
| Operating margin | 9.9% | 8.7% |
| Dividend yield | 0.57% | 0.54% |
| Sales growth, 3 years (yearly) | 31.4% | 9.7% |
| Profit growth, 3 years (yearly) | 23.6% | — |
| 1-year return | -31.8% | -19.6% |
| Revenue, last 12 months | ₹2,432 cr | ₹8,608 cr |
| Net profit, last 12 months | ₹170 cr | ₹352 cr |
| Latest quarter | Jun 2026 | Jun 2026 |
| Quarter net profit | ₹38 cr | ₹57 cr |
| Quarter profit vs a year earlier | -32.1% | -45.1% |
| Promoter holding | 75.00% | 47.68% |
| Health check | Average (4.4/10) | Average (4.2/10) |
Common questions
Which has a higher P/E, AstraZeneca Pharma India Limited or Jubilant Pharmova Limited?
AstraZeneca Pharma India Limited trades at the higher P/E (93.8 against 41.7). A higher P/E means the market pays more for each rupee of past earnings; on its own it does not say which is better.
Which earns a higher return on equity?
AstraZeneca Pharma India Limited (23.9% against 6.0%).
Which carries more debt?
Jubilant Pharmova Limited has the higher debt-to-equity ratio (0.51 against 0.13).